inPractice® - Host Factors

Advanced fibrosis/cirrhosis is associated with reduced likelihood of SVR, including to DAA therapy
IL28B genotype is associated with interferon responsiveness and SVR to interferon-based therapy^{[Ge 2009; Tanaka 2009; Thomas 2009]}
- Patients with favorable CC genotype have high rates of SVR to peginterferon/ribavirin dual therapy; incremental benefit with PI-based therapy, although many such patients will qualify for shortened PI therapy^{[Jacobson 2011b; Poordad 2012]}